Wednesday, August 04, 2021 12:28:45 AM
<<<<<< If the studies were good enough for the FDA to clear, why not good enough for insurance companies? >>>>>>>
Similar to the NHS local CCGs refusing to authorize doctors to prescribe ActiPatch, an NHS approved medical device, insurance companies are slow to adopt new treatments.
Even with BIEL demonstrating how ActiPatch use would lower patient use of medical care and therefor save CCGs/Insurers money they resist. They have a business model set up around 'a drug for every problem' and are evidently satisfied with the results despite the side effects, one of those being 600,000 opioid deaths.
After one Clearance for eyelid surgery the FDA dragged their feet for 13 years before reclassifying ActiPatch from a Class 3 Device, life sustaining products, to the less regulated Class 2 Device. So the FDA also has a history of maintaining the status quo.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM